サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784877

中絶薬の世界市場

Abortion Drugs

出版日
ページ情報
英文 280 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
中絶薬の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 280 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

中絶薬の世界市場は2030年までに379億米ドルに達する見込み

2024年に255億米ドルと推定される中絶薬の世界市場は、分析期間2024-2030年にCAGR 6.9%で成長し、2030年には379億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるミフェプリストンは、CAGR 8.7％を記録し、分析期間終了時には65億米ドルに達すると予想されます。ミソプロストールセグメントの成長率は、分析期間中CAGR 7.2％と推定されます。

米国市場は69億米ドルと推定、中国はCAGR 10.9％で成長予測

米国の中絶薬市場は、2024年に69億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに80億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3％と6.7％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の中絶薬市場- 主要動向と促進要因のまとめ

中絶薬市場の成長を牽引しているのは？

薬による中絶に対する安全で効果的な選択肢に対する需要の高まりが、中絶薬市場の主な促進要因です。リプロダクティブ・ヘルスと権利に関する意識の高まりに伴い、女性はより侵襲的でなく、よりプライベートな外科的中絶方法に代わるものを求めています。ミフェプリストンやミソプロストールのような薬物によって促進される薬による中絶は、早期の妊娠を終了させるための安全で便利な選択肢を提供し、世界中でこれらの製品の採用に拍車をかけています。

規制状況の進展も市場の成長に寄与しています。特にリプロダクティブ・ライツ（性と生殖に関する権利）に関する世界の議論を受け、多くの国が法律やガイドラインを改正し、中絶薬へのアクセス拡大に取り組んでいます。このような変化により、中絶薬は薬局や診療所、さらには遠隔医療プラットフォームでも利用できるようになり、都市部、農村部、十分なサービスを受けていない地域の女性がよりアクセスしやすくなっています。この変化は、外科的中絶サービスが限られていたり、利用できなかったりする地域では特に重要です。

遠隔医療の役割の増大は、市場成長を促進するもう一つの重要な要因です。中絶医療に遠隔医療サービスが統合されたことで、女性はヘルスケア専門家に遠隔で相談し、中絶薬に便利にアクセスできるようになりました。この動向はCOVID-19の大流行時に勢いを増し、ヘルスケアプロバイダーと患者が同様にデジタルソリューションを受け入れるにつれて繁栄を続けています。遠隔医療が提供する利便性、プライバシー、アクセシビリティは、中絶薬の普及を促進し、世界の広がりを見せています。

技術の進歩は中絶薬市場をどのように形成していますか？

医薬品研究の進歩は、薬効と安全性プロファイルを改善することにより、中絶薬市場を大きく形成しています。ドラッグの製剤やデリバリーのメカニズムにおける革新は、より高い成功率、より少ない副作用、患者の回復時間の短縮を保証しています。例えば、ミフェプリストンとミソプロストールの組み合わせが改良され、出血や痛みをより効果的にコントロールできるようになりました。このような進歩により、ヘルスケア提供者と患者の薬による中絶方法の使用に対する信頼が高まっています。

デジタルヘルス技術もまた、中絶薬の処方や配布の方法を変えつつあります。テレヘルスプラットフォームやモバイルヘルスアプリは、女性が中絶治療に慎重かつ便利にアクセスすることを可能にしています。これらのプラットフォームを通じて、患者は認可を受けたヘルスケア専門家と相談し、処方箋を受け取り、中絶薬を直接自宅に届けることができます。中絶医療とデジタルツールの統合は、特に遠隔地や十分なサービスを受けていない地域において、アクセスを改善し、医療ガイドラインの遵守を確実なものにしています。

さらに、患者とヘルスケア提供者双方のための教育・支援ツールの開発が市場を強化しています。モバイルアプリやオンラインプラットフォームは、中絶薬の使用に関するステップバイステップのガイダンスを提供し、進捗状況を監視し、副作用を管理するために使用されています。これらのリソースは、女性がプロセスを通じて信頼できる情報とサポートを利用できるようにし、転帰と患者の満足度を向上させる。デジタル技術が進化し続けるにつれて、中絶医療へのアクセスを拡大し、その質を向上させる上で、デジタル技術が果たす役割はさらに大きくなると予想されます。

女性とヘルスケアシステムにとっての中絶薬の利点とは？

女性にとって、中絶薬は安全で、プライバシーが守られ、非侵襲的な早期妊娠中絶の選択肢を提供します。薬による中絶は、特にヘルスケアのインフラが限られている地域では、一般的に外科手術よりも費用がかからず、利用しやすい方法です。中絶薬を利用することで、女性は自分のリプロダクティブ・ヘルスをコントロールし、安全で快適な環境で決断を下すことができます。さらに、薬による中絶は回復にかかる時間が短く、合併症のリスクも低いため、多くの女性にとって好ましい選択です。

中絶薬はまた、外科的処置や病院での治療の必要性を減らすことで、ヘルスケアシステムの負担を軽減します。女性が早期中絶を自宅や外来で管理できるようにすることで、薬による中絶は他の重要なヘルスケアニーズにリソースを割くことができます。これは、ヘルスケア施設や人材が過剰になりがちな低資源環境では特に有益です。中絶薬を遠隔医療プラットフォームと統合することで、対面診療を減らし、ケアの提供を効率化することができます。

さらに、中絶薬は、世界のリプロダクティブ・ライツを推進する上で重要な役割を果たしています。安全で効果的な中絶治療へのアクセスを向上させることで、女性の健康と生命に重大なリスクをもたらす危険な中絶行為の蔓延を減らすことができます。また、中絶薬の利用可能性は、女性が生殖に関する選択について自律性を行使できるようにすることで、ジェンダー平等にも貢献し、より広範な社会的・経済的利益を支えています。

中絶薬の市場促進要因は何ですか？

リプロダクティブ・ヘルス（性と生殖に関する健康と権利）に対する意識の高まりは、中絶薬市場の主要促進要因です。女性が妊娠を管理する選択肢について知識を深めるにつれ、安全で効果的な中絶薬への需要が高まっています。この動向は、リプロダクティブ・ヘルスケアへのアクセスを促進し、中絶ケアの障壁をなくすための世界のアドボカシー活動によってさらに後押しされています。

規制の変更や政策支援も市場を牽引しています。政府やヘルスケア組織は、法律の改正、流通経路の拡大、薬による中絶を公衆衛生システムに組み込むことによって、中絶薬へのアクセスを改善しようと取り組んでいます。こうした取り組みは、中絶に関する法律が制限されていたり、手術サービスへのアクセスが制限されていたりする地域では特に影響が大きく、より多くの女性が安全で効果的な治療の恩恵を受けることができるようになります。

最後に、遠隔医療の普及が市場を加速させています。遠隔診察や処方サービスを可能にすることで、遠隔医療プラットフォームは中絶薬へのアクセスを拡大し、そのプロセスを女性にとってより便利でプライベートなものにしています。薬剤製剤やドラッグデリバリーシステムの進歩と相まって、これらの促進要因が中絶薬市場を今後数年間の持続的成長と革新に向けて位置づけています。

セグメント

薬剤クラス（ミフェプリストン、ミソプロストール、ピトシン、ヘマベート、カルボプロスト、その他薬剤クラス別）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例

  • Cipla Ltd
  • Corcept Therapeutics, Incorporated
  • Dr. Reddy's Laboratories, Inc
  • Exelgyn
  • GenBioPro
  • Kabir Lifesciences
  • Lupin Limited
  • Pfizer Inc.
  • Sao Kim Pharmaceutical JSC
  • Somacare
  • Synokem Pharmaceuticals Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals USA, Inc.
  • Torrent Pharmaceuticals Ltd
  • VIVAN Life Sciences Pvt. Limited.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP28934

Global Abortion Drugs Market to Reach US$37.9 Billion by 2030

The global market for Abortion Drugs estimated at US$25.5 Billion in the year 2024, is expected to reach US$37.9 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Mifepristone, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.5 Billion by the end of the analysis period. Growth in the Misoprostol segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.9 Billion While China is Forecast to Grow at 10.9% CAGR

The Abortion Drugs market in the U.S. is estimated at US$6.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.0 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Abortion Drugs Market - Key Trends & Drivers Summarized

What Is Driving the Growth of the Abortion Drugs Market?

The rising demand for safe and effective options for medical abortion is a major driver of the Abortion Drugs market. With increasing awareness about reproductive health and rights, women are seeking alternatives to surgical abortion methods that are less invasive and more private. Medical abortion, facilitated by drugs such as mifepristone and misoprostol, provides a safe and convenient option for terminating early pregnancies, fueling the adoption of these products worldwide.

Evolving regulatory landscapes are also contributing to market growth. Many countries are working to expand access to abortion drugs by revising laws and guidelines, especially in the wake of global discussions around reproductive rights. These changes are enabling the availability of abortion drugs in pharmacies, clinics, and even via telemedicine platforms, ensuring greater accessibility for women in urban, rural, and underserved regions. This shift is particularly significant in regions where surgical abortion services are limited or unavailable.

The increasing role of telemedicine is another significant factor driving market growth. The integration of telehealth services with abortion care has enabled women to consult healthcare professionals remotely and access abortion drugs conveniently. This trend gained momentum during the COVID-19 pandemic and continues to thrive as healthcare providers and patients alike embrace digital solutions. The convenience, privacy, and accessibility offered by telemedicine are enhancing the adoption of abortion drugs and expanding their reach globally.

How Are Technological Advancements Shaping the Abortion Drugs Market?

Advancements in pharmaceutical research are significantly shaping the Abortion Drugs market by improving drug efficacy and safety profiles. Innovations in drug formulations and delivery mechanisms are ensuring higher success rates, fewer side effects, and shorter recovery times for patients. For instance, improved combinations of mifepristone and misoprostol are providing more effective outcomes, with better control of bleeding and pain. These advancements are increasing the confidence of healthcare providers and patients in using medical abortion methods.

Digital health technologies are also transforming how abortion drugs are prescribed and distributed. Telehealth platforms and mobile health apps are enabling women to access abortion care discreetly and conveniently. Through these platforms, patients can consult with licensed healthcare professionals, receive prescriptions, and have abortion drugs delivered directly to their homes. The integration of digital tools with medical abortion care is improving access and ensuring compliance with medical guidelines, especially in remote and underserved regions.

Additionally, the development of educational and support tools for both patients and healthcare providers is enhancing the market. Mobile apps and online platforms are being used to provide step-by-step guidance on the use of abortion drugs, monitor progress, and manage side effects. These resources ensure that women have access to reliable information and support throughout the process, improving outcomes and patient satisfaction. As digital technologies continue to evolve, they are expected to play an even greater role in expanding access to and improving the quality of abortion care.

What Are the Benefits of Abortion Drugs for Women and Healthcare Systems?

For women, abortion drugs provide a safe, private, and non-invasive option for terminating early pregnancies. Medical abortion is typically less costly and more accessible than surgical procedures, especially in regions with limited healthcare infrastructure. The availability of abortion drugs empowers women to take control of their reproductive health and make decisions in a setting that feels safe and comfortable. Additionally, the shorter recovery times and lower risk of complications associated with medical abortion make it a preferred choice for many women.

Abortion drugs also reduce the burden on healthcare systems by decreasing the need for surgical procedures and hospital-based care. By enabling women to manage early abortions at home or in outpatient settings, medical abortion frees up resources for other critical healthcare needs. This is particularly beneficial in low-resource settings where healthcare facilities and personnel are often overstretched. The integration of abortion drugs with telemedicine platforms further enhances efficiency by reducing in-person visits and streamlining care delivery.

Moreover, abortion drugs play a critical role in advancing global reproductive rights. By increasing access to safe and effective abortion care, these drugs help reduce the prevalence of unsafe abortion practices that pose significant risks to women’s health and lives. The availability of abortion drugs also contributes to gender equality by ensuring that women can exercise autonomy over their reproductive choices, supporting broader societal and economic benefits.

What Are the Key Market Drivers for Abortion Drugs?

The increasing awareness of reproductive health and rights is a major driver of the Abortion Drugs market. As women become more informed about their options for managing pregnancies, the demand for safe and effective abortion drugs is growing. This trend is further supported by global advocacy efforts to promote access to reproductive healthcare and eliminate barriers to abortion care.

Regulatory changes and policy support are also driving the market. Governments and healthcare organizations are working to improve access to abortion drugs by revising laws, expanding distribution channels, and integrating medical abortion into public health systems. These efforts are particularly impactful in regions with restrictive abortion laws or limited access to surgical services, enabling more women to benefit from safe and effective care.

Finally, the growing adoption of telemedicine is accelerating the market. By enabling remote consultations and prescription services, telehealth platforms are expanding access to abortion drugs and making the process more convenient and private for women. Combined with advancements in drug formulations and delivery systems, these drivers are positioning the Abortion Drugs market for sustained growth and innovation in the coming years.

SCOPE OF STUDY:

The report analyzes the Abortion Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost, Other Drug Classes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Cipla Ltd
  • Corcept Therapeutics, Incorporated
  • Dr. Reddy's Laboratories, Inc
  • Exelgyn
  • GenBioPro
  • Kabir Lifesciences
  • Lupin Limited
  • Pfizer Inc.
  • Sao Kim Pharmaceutical JSC
  • Somacare
  • Synokem Pharmaceuticals Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals USA, Inc.
  • Torrent Pharmaceuticals Ltd
  • VIVAN Life Sciences Pvt. Limited.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Abortion Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Non-Surgical Termination Methods Throws the Spotlight on Medical Abortion Drugs
    • Shifting Socio-Political Landscapes and Reproductive Rights Debates Propel Market Visibility and Access Challenges
    • Growing Preference for Privacy and Convenience Expands the Addressable Market for Home-Use Abortion Pills
    • Increased Availability Through Telemedicine Strengthens the Business Case for Digitally Accessible Abortion Drug Services
    • Global Public Health Advocacy for Reproductive Autonomy Drives Policy Reforms and Market Expansion
    • Technological Advancements in Drug Formulation and Dosage Optimization Drive Product Differentiation
    • Rising Incidence of Unintended Pregnancies in Developing Regions Fuels Demand for Cost-Effective Medical Termination Options
    • NGO and Government Support for Women's Health Initiatives Enhances Access in Underserved Geographies
    • Cross-Border E-Commerce and Mail-Order Services Generate New Distribution Channels and Compliance Challenges
    • Integration of Abortion Drugs in Family Planning Programs Drives Market Penetration in Public Health Systems
    • Backlash Against Legal Restrictions Creates Parallel Demand Through Informal and Grey Market Channels
    • Pharmaceutical Pipeline Innovation and Generic Drug Manufacturing Expand Affordability and Availability
    • Risk Management, Safety Monitoring, and Adverse Event Surveillance Systems Strengthen Trust in Medical Abortion Protocols
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Abortion Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Abortion Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mifepristone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Mifepristone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Mifepristone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Misoprostol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Misoprostol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Misoprostol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pitocin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pitocin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Pitocin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hemabate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hemabate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hemabate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Carboprost by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Carboprost by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Carboprost by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Abortion Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Abortion Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Abortion Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Abortion Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION